INVESTOR ALERT: Investigation Of Moonlake Immunotherapeutics (MLTX) Announced By Holzer & Holzer, LLC

2025-09-30 10:31:41

(MENAFN- GlobeNewsWire - Nasdaq) ATLANTA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether MoonLake Immunotherapeutics (“MoonLake” or the“Company”) (NASDAQE: MLTX) complied with federal securities laws. On September 28, 2025, MoonLake reported results from its VELA-1 and VELA-2 Phase 3 program, disclosing that in“VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy.” Following this news, the price of the Company's stock dropped.

If you purchased MoonLake stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at ... or Joshua Karr, Esq. at ... , call our toll-free number at (888) 508-6832, or visit our website at to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, , and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
...

MENAFN30092025004107003653ID1110131266

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.